1. SGLT2 Inhibitors in Aging-Related Cardiovascular Disease: A Review of Potential Mechanisms.
- Author
-
Zhang Y, He Y, Liu S, Deng L, Zuo Y, Huang K, Liao B, Li G, and Feng J
- Subjects
- Humans, Aged, Aging, Cardiovascular Diseases drug therapy, Cardiovascular Diseases prevention & control, Cardiovascular Diseases etiology, Sodium-Glucose Transporter 2 Inhibitors adverse effects, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 complications, Cardiovascular System, Heart Failure drug therapy
- Abstract
Population aging combined with higher susceptibility to cardiovascular diseases in older adults is increasing the incidence of conditions such as atherosclerosis, myocardial infarction, heart failure, myocardial hypertrophy, myocardial fibrosis, arrhythmia, and hypertension. sodium-glucose cotransporter 2 inhibitors (SGLT2i) were originally developed as a novel oral drug for patients with type 2 diabetes mellitus. Unexpectedly, recent studies have shown that, beyond their effect on hyperglycemia, SGLT2i also have a variety of beneficial effects on cardiovascular disease. Experimental models of cardiovascular disease have shown that SGLT2i ameliorate the process of aging-related cardiovascular disease by inhibiting inflammation, reducing oxidative stress, and reversing endothelial dysfunction. In this review, we discuss the role of SGLT2i in aging-related cardiovascular disease and propose the use of SGLT2i to prevent and treat these conditions in older adults., (© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2023
- Full Text
- View/download PDF